$NVO expands legal battle over compounded weight loss drugs Aug. 05, 2025 $HIMS

Novo Nordisk (NVO) on Tuesday announced 14 new lawsuits filed against vendors selling cheaper compounded versions of its blockbuster medication semaglutide, marketed as Wegovy for patients with obesity.
The announcement came a day after the digital weight-loss company Noom launched low-dose copies of semaglutide at a sharp discount to the branded product in a market dominated by its telehealth rival Hims & Hers Health (HIMS).
“The defendants named in these lawsuits employ tactics that deceive patients into believing compounded products have been reviewed and approved by the FDA or have equivalent safety or effectiveness as Novo Nordisk's approved semaglutide medicines,” NVO said.

Compounded pharmacies have been barred from selling copies of semaglutide after the FDA officially declared that the shortage for the popular GLP-1 injectable ended early this year.

“No one should have to gamble with their health by using knockoff drugs made with ingredients that lack oversight and safety standards," Novo’s U.S. head of operations, Dave Moore, said, adding, "We urge regulators to enforce laws designed to protect public health."

The latest lawsuits bring the total number of cases filed by the company in federal courts to 132 across 40 states.